IL-8 receptor modified CAR T cell therapy for pediatric high-grade glioma

Phase I Study -To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)

This study is testing a new type of CAR T cell therapy for children with a specific brain cancer to see if it can work safely alongside their regular treatment.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Ages: 4 Years to 18 Years
• Sex: All
• Sponsor: University of Florida (other)
• Drugs / interventions: CAR T, radiation
• Locations: 1 site (Gainesville, Florida)
• Trial ID: NCT06946680 on ClinicalTrials.gov

What this trial studies

This phase I clinical trial aims to evaluate the safety and feasibility of using IL-8 receptor modified CD70 CAR T cell therapy in children diagnosed with CD70 positive high-grade glioma. Patients will have their peripheral blood mononuclear cells collected before starting standard chemotherapy and radiation treatment. After confirming the tumor's CD70 status, the modified CAR T cells will be produced and administered following a lymphodepletion regimen. The study will assess the response to this innovative immunotherapy approach in conjunction with standard treatment.

Who should consider this trial

Good fit: Ideal candidates are newly diagnosed pediatric patients with CD70 positive high-grade glioma and a performance status of over 70%.

Not a fit: Patients with a previous history of brain tumors or those whose tumors do not express CD70 may not benefit from this therapy.

Why it matters

Potential benefit: If successful, this therapy could provide a novel and effective treatment option for pediatric patients with high-grade glioma, potentially improving survival rates.

How similar studies have performed: While CAR T cell therapies have shown promise in other cancers, this specific approach targeting CD70 in pediatric high-grade glioma is novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

* Newly-diagnosed pHGG based on the absence of a previous history of brain tumor (WHO Grade III-IV glioma) by histopathology.
* CD70 positive (≥20%, 1+) The tumors from the surgical resection by immunohistochemistry will be confirmed by a validated assay performed at UF Health Pathology, a certified Lab.

  o CD70 tumor expression performed on paraffin-embedded tumor specimens will be evaluated. Tumor expression will be scored on a scale of 0 to 3 staining intensity: 0 = Negative
  1. = Low level
  2. = Moderate level
  3. = High level
* Karnofsky Performance Status (KPS) or Lansky Performance Score (LPS) of \> 70% (Appendix C) Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score provided the neurological deficit is stable.
* CBC with differential with adequate bone marrow function as defined below:

  * Absolute neutrophil count (ANC) ≥ 1000 cells/mm3.
  * Platelet count ≥ 100,000 cells/mm3.
  * Hemoglobin ≥ 10 g/dl. (The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)
* Adequate renal function as defined below:

  o Serum creatinine \< 1.5 x institutional upper limit of normal for age and gender. Patients who do not meet the criteria but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m2 are eligible
* Adequate hepatic function as defined below:

  * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) for age
  * ALT ≤ 3 times institutional upper limits of normal for age
  * AST ≤ 3 times institutional upper limits of normal for age
* Signed informed consent, or for patients age \<18, parental permission, and, as appropriate, assent from pediatric patients age ≥12. If the patient's mental status precludes their informed consent, the legally authorized representative may give informed consent. Consent or permission/assent will be obtained at screening (before PBMC collection) and before treatment with CAR T-cells.
* For females of childbearing potential, a negative serum pregnancy test at enrollment.
* Women of childbearing potential (WOCBP) must be willing to use an acceptable contraceptive method to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.
* Males with female partners of childbearing potential must agree to practice adequate contraceptive methods throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug.

Exclusion Criteria:

* Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3years. (In situ cancer is permissible)
* Spinal metastasis and leptomeningeal involvement.
* Patients with Bulky Tumors:

  * 3 cm in a single dimension (post-surgery)
  * Tumor causing uncal herniation or mass effect leading to midline shift with or without symptoms or signs of impending herniation or
  * Obstruction to CSF flow
* Recurrent or multifocal malignant gliomas.
* The patient is not a candidate for cellular therapy as assessed by the study bone marrow transplant physician.
* Known immunosuppressive disease or human immunodeficiency virus (HIV) infection.

HIV-positive patients are ineligible due to the unknown safety and efficacy of infusing these patients with CAR T cells genetically modified using retroviral vectors. Additionally, the immunosuppression used for treatment in this study will pose an unacceptable risk.

• Concurrent illness: Patients with active autoimmune disease, documented history of autoimmune disease/syndrome, or any other condition that requires ongoing systemic steroids or systemic immunosuppressive agents, except

* Patients with vitiligo or resolved asthma/atopy
* Patients with hypothyroidism stable on hormone replacement or Sjogren's syndrome
* Patients requiring physiologic doses of corticosteroids (up to 0.5 mg/m2/day dexamethasone equivalent)

  * History of or ongoing pneumonitis or significant interstitial lung disease.
  * Ongoing or active uncontrolled infection.
  * Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator, would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
  * Patients with any of the following cardiac diseases:
* New York Heart Association (NYHA) functional class III or IV
* Clinically significant cardiac arrhythmia including, but not limited to, Torsade de pointes or requiring a pacemaker
* Left ventricular ejection fraction below 50% as determined by echocardiography (ECHO)

  * Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant.
  * Patients treated on any other therapeutic clinical protocols within 30 days prior to enrollment.
  * For females of childbearing potential, a negative serum pregnancy test at enrollment.

Where this trial is running

Gainesville, Florida

• University of Florida Health Children's Hospital — Gainesville, Florida, United States (RECRUITING)

Study contacts

• Principal investigator: Ashley Ghiaseddin, MD — University of Florida
• Study coordinator: Marcia Hodik, RN, BSHS, CCRP

Conditions: High-grade Glioma, CAR T Cell, Brain Tumor, Brain Cancer, Immunotherapy, Glioblastoma